These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29665657)

  • 1. Recent advances in the diagnosis and management of primary myelofibrosis.
    Takenaka K; Shimoda K; Akashi K
    Korean J Intern Med; 2018 Jul; 33(4):679-690. PubMed ID: 29665657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recent advances in the treatment of myelofibrosis].
    Takenaka K
    Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the understanding and management of primary myelofibrosis.
    Cervantes F; Pereira A
    Curr Opin Oncol; 2011 Nov; 23(6):665-71. PubMed ID: 21892083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
    Alshemmari SH; Rajan R; Emadi A
    Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A
    Am J Hematol; 2016 Jan; 91(1):50-8. PubMed ID: 26492355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
    Kourie HR; Ameye L; Paesmans M; Bron D
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I Diagnose Primary Myelofibrosis.
    Prakash S; Orazi A
    Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
    He ZP; Tian HY; Tan M; Wu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
    N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driver mutations in primary myelofibrosis and their implications.
    Szuber N; Tefferi A
    Curr Opin Hematol; 2018 Mar; 25(2):129-135. PubMed ID: 29256926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Barbui T; Thiele J; Vannucchi AM; Tefferi A
    Blood Cancer J; 2015 Aug; 5(8):e337. PubMed ID: 26832847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of molecular profiling on the management of patients with myelofibrosis.
    Pastor-Galán I; Martín I; Ferrer B; Hernández-Boluda JC
    Cancer Treat Rev; 2022 Sep; 109():102435. PubMed ID: 35839532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.